Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Corticosteroid vs Tocilizumab in COVID-19 Pneumonia
NCT05133635Phase 4Withdrawn
- Sponsor
- Marmara University
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of methylprednisolone, tocilizumab in COVID-19 pneumonia, cytokine release syndrome (CRS), sponsored by Marmara University. Planned start Feb 2021; status: withdrawn.
02
Drugs
methylprednisolonetocilizumab
03
Conditions
COVID-19 pneumoniacytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT05133635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133635.